FDA approves Bayer’s asundexian (Sunharbo), the first Factor XIa inhibitor, for secondary stroke prevention. FDA has granted ...
AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward ...
Ignite Proteomics’ senior clinical research scientist discusses how flaws in testing tumors may lead to some patients not receiving the correct treatment.
Single-partner platforms can unify manufacturers, prescribers, and patients to eliminate gaps, cut costs, and boost treatment ...
Unnatural Products for up to $1.15 billion to expand its immunology capabilities, GiftHealth’s Chip Parkinson on how single-partner platforms can transform the prescription journey, and Partha Anbil ...
Unnatural Products, adding a macrocyclic peptide discovery platform to complement its antibody engineering. argenx signed a ...
Ignite Proteomics measures phosphorylation states to show which proteins are actively driving a tumor—guiding therapy beyond ...
How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer ...
Hims & Hers partners with Eli Lilly to sell Zepbound and Foundayo directly on its platform, Novo Nordisk terminates its ...
As Medicare negotiation, PBM reform, and cash-pay channels converge, winning on auditable net value matters more than cutting ...
The agreement provides access for prescribed patients to Lilly's obesity medicines self-pay pricing starting at $149 per ...
The top barrier to AI adoption among pharma commercial leaders is compliance uncertainty, and the fix may be governance that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results